-

11:55:09 AM

IXHL Stock News

IXHL - Incannex Healthcare Limited

05/17/22 7:55 AM

Nasdaq : IXHL

Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea

Incannex Healthcare Limited (NASDAQ: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical

RHEA-AI

neutral

05/12/22 7:55 AM

Nasdaq : IXHL

acquisition

Incannex Completes Share Sale and Purchase Agreement to Wholly Acquire APIRx Pharmaceuticals USA, LLC

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical

RHEA-AI

neutral

05/10/22 7:55 AM

Nasdaq : IXHL

Incannex announces IHL-216A observed to have a neuroprotective effect in a rodent model of sports concussion; rapidly restores spatial memory post-concussion

Highlights:The study compared IHL-216A to its component drugs, cannabidiol (CBD) and isoflurane, in a model developed in collaboration with the US National Football League (NFL) IHL-216A restored spatial memory after twenty-four hours in injured rodent models whilst those that only received the

RHEA-AI

neutral

04/28/22 7:55 AM

Nasdaq : IXHL

Quarterly Activities Report and Appendix 4C Cash Flow Statement

Highlights:Positive phase 2a clinical trial results for IHL-42X with 60% of trial participants experiencing at least a 55% reduction in the Apnoea Hypopnea Index ('AHI') 20% of IHL-42X clinical trial participants experienced a reduction in AHI of greater than 80% completes comprehensive in vivo

RHEA-AI

positive

04/28/22 7:25 AM

Nasdaq : IXHL

Incannex Completes Loyalty Option Program to Raise A$23.6M; Current Cash at Bank is Approximately A$40.0M

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical

RHEA-AI

neutral

03/24/22 7:55 AM

Nasdaq : IXHL

acquisition

Incannex to Acquire APIRx Pharmaceuticals USA, LLC

Highlights:APIRx has twenty-two (22) active clinical and pre-clinical research and development projects therapeutic candidates are targeted at treating pain, dementia, Parkinson's disease, restless leg syndrome, gastrointestinal diseases, periodontitis, addiction disorders, skin conditions and

RHEA-AI

neutral

03/10/22 7:55 AM

Nasdaq : IXHL

clinical trial

Incannex observes substantial reduction in AHI in preliminary results of clinical trial assessing IHL-42X in patients with OSA; proceeds to pivotal studies

Highlights:20% of trial participants experienced a reduction in AHI of greater than 80% (range: 82.7% to 91.5%) during at least one treatment compared to baseline 60% of trial participants experienced a reduction in AHI of greater than 50%

RHEA-AI

positive

03/03/22 7:55 AM

Nasdaq : IXHL

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs,

RHEA-AI

positive

02/28/22 7:55 AM

Nasdaq : IXHL

Incannex Completes Listing of American Depositary Shares on Nasdaq; Rings Nasdaq Closing Bell

Incannex Healthcare Limited (Nasdaq: IXHL) (ASX: IHL), ('Incannex' or the 'Company') a clinical-stage pharmaceutical company developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for unmet medical needs,

RHEA-AI

neutral